Capricor Therapeutics

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Capricor Therapeutics reports strong Q4 performance and advances DMD therapy

Capricor Therapeutics showcased strong financial performance, progress in DMD therapy, and strategic partnerships with Nippon Shinyaku and NS Pharma.
The company faces challenges in FDA interactions, share sales, and potential acquisition decisions, but opportunities lie in market expansion and community engagement.
Overall, Capricor's confidence in its therapies and partnerships positions it well for future growth and impact in the Duchenne Muscular Dystrophy space.
The call concluded with gratitude towards participants, supporters, and the Capricor team, highlighting a positive outlook for the company's future endeavors.

Capricor Therapeutics advances DMD programs and secures Japan distribution

Capricor Therapeutics made significant progress in Q1 2023 with advancements in DMD programs, manufacturing, and clinical trials.
While facing financial losses, the company's strategic strengths include FDA discussions, partnerships, and international expansion.
Challenges in financial stability and operational efficiency need to be addressed, but opportunities in funding, market expansion, and innovation are promising.

Capricor Therapeutics reports Q2 progress with positive clinical outcomes

Capricor Therapeutics showcased solid financial performance amid ongoing R&D investments, with a focus on advancing innovative therapies for Duchenne muscular dystrophy.
The company's strengths lie in positive clinical trial outcomes, regulatory support, and strategic board additions, positioning Capricor for future growth and success.
Challenges include financial sustainability, trial coordination, and manufacturing scalability, which require careful management to navigate effectively.
Opportunities in new indications, partnerships, upcoming milestones, and technology advancement offer avenues for expansion, value creation, and competitive differentiation.

Capricor Therapeutics achieves enrollment goal, eyes FDA approval acceleration

Capricor Therapeutics is making significant strides in its clinical trials and manufacturing capabilities, supported by a strong financial position. While challenges exist in managing expenses and navigating regulatory processes, the company is well-positioned to capitalize on growth opportunities in the biopharmaceutical sector.

Capricor Therapeutics reports positive trial results and strategic partnerships for growth

Capricor Therapeutics' Q4 2023 performance reflects a strong financial position but with a net loss, driven by positive trial results for CAP-1002 in DMD.
The company's strengths include successful trial outcomes, strategic partnerships, and advancements in exosome technology development.
Challenges include operational losses, regulatory hurdles, and market competition, while opportunities exist in partnerships, FDA interactions, and technology development.
Overall, Capricor Therapeutics is poised for growth with a focus on commercialization, regulatory progress, and expanding therapeutic applications.

Capricor Therapeutics excels in Q1 2024, poised for market expansion

Capricor Therapeutics shows strong financial performance and progress in DMD trial, positioning CAP-1002 favorably in the market.
Strategic focus on regulatory alignment, commercial readiness, and potential expansions highlight growth opportunities.
Challenges in regulatory compliance, operational execution, and market competition require proactive management strategies.
Overall, Capricor's advancements in therapy development and market positioning indicate a promising outlook for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

– The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 –

Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19

Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2020 Results - Earnings Call Transcript

Exosome Platform for COVID-19   -Novel Multivalent Exosome mRNA and VLP Vaccine Candidates Underway in Animal Studies-  -Preclinical Data Shows Positive Antibody Response-

Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET Company to Host Conference Call and Webcast, August 6, 2020, at 4:30 p.m. ET

Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6

Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Capricor Therapeutics (CAPR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Capricor Therapeutics Inc. (CAPR) CEO Linda Marban on Q1 2020 Results - Earnings Call Transcript

Capricor (CAPR) delivered earnings and revenue surprises of 16.67% and -11.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Capricor Therapeutics (CAPR) Reports Q1 Loss, Lags Revenue Estimates

Duchenne Muscular Dystrophy Program   -Final Top-Line  12-month Results from Phase II Randomized, Double-blind, Placebo-controlled HOPE-2- Study Demonstrated  Improved Performance of Upper Limb (PUL) 2.0 (p=0.05)-

Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Capricor Therapeutics Inc.’s (NASDAQ: CAPR) shares soared after data that pointed to a 100 percent survival rate in critical COVID-19 patients treated with new CAP-1002 cardiac cell therapy was released.

Capricor Therapeutics Shares Soar 250% On Successful COVID-19 Treatment News

U.S. FDA Approves Company’s Expanded Access Protocol to Treat Additional Patients U.S. FDA Approves Company’s Expanded Access Protocol to Treat Additional Patients

New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002

­LOS ANGELES, April 03, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment or prevention of serious diseases, today announced it is providing CAP-1002, its novel cell therapy to patients with advanced COVID-19 under the compassionate use pathway.

Capricor Initiates Compassionate Use Program for Severe COVID-19 Patients using CAP-1002, its Novel Cell Therapy

Masimo

Moderna

QIAGEN

Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.

4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis

Capricor Therapeutics' (CAPR) CEO Linda Marban on Q4 2019 Results - Earnings Call Transcript

Company Appoints Stephen Gould, Ph.D. as Executive Consultant for its Exosomes Program Company Appoints Stephen Gould, Ph.D. as Executive Consultant for its Exosomes Program

Capricor Therapeutics Announces Strategic Plan for Exosome Platform Technology Products Expansion

LOS ANGELES, Dec.  19, 2019  (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced the closing of the previously announced offering priced at-the-market of 4,139,477 shares of the Company’s common stock (or common stock equivalents), at a purchase price of $1.226 per share and associated warrant. In addition, select members of the Company's Board of Directors participated in the offering. Each share of common stock (or common stock equivalent) offered was sold with a warrant to purchase one share of common stock at an exercise price of $1.10 per share and a five-year term.

Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

LOS ANGELES, Dec.  17, 2019  (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced that it has entered into a definitive securities purchase agreement with a single, healthcare-dedicated institutional investor for the purchase in an  offering priced at-the-market of 4,078,304 shares of the Company’s common stock (or common stock equivalents), at a purchase price of $1.226 per share and associated warrant. In addition, select members of the Company's Board of Directors are participating in the offering. Each share of common stock (or common stock equivalent) offered was sold with a warrant to purchase one share of common stock at an exercise price of $1.10 per share and a five-year term.

Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market

Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q3 2019 Results - Earnings Call Transcript

Call Scheduled for Thursday, October 24th at 10:30am Eastern Time

Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)

--Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies--    --Company to Host Conference Call Today at 5:30 AM PT / 8:30 AM ET--

Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months

Capricor Therapeutics shares CAPR, -0.32% rose 3.6% in premarket trade Tuesday, after the clinical-stage biotech said the U.s.

Capricor Therapeutics shares climb 3.6% on news FDA to meet to discuss DMD treatment

Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies Company Exploring Potential for Accelerated Approval under RMAT Designation, an Expedited Program for Regenerative Therapies

Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy

Dr. Craig McDonald to Provide Update in Late Breaking Oral Presentation Dr. Craig McDonald to Provide Update in Late Breaking Oral Presentation

Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society

LOS ANGELES, Sept.  06, 2019  (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR),  a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today announced that that Linda Marbán, Ph.D., its president and chief executive officer, is scheduled to present at two upcoming conferences:

Capricor Therapeutics to Present at Upcoming Conferences

Capricor Therapeutics' (CAPR) CEO Linda Marbán on Q2 2019 Results - Earnings Call Transcript

Capricor (CAPR) delivered earnings and revenue surprises of 26.25% and 86.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

News for Capricor Therapeutics Stock (CAPR)